Table 2.
Results of Landmark and Bootstrap Analyses for Overall Survival by Progression Status at 3 Months, 6 Months, 9 Months, and 12 Months After the Initiation of Targeted Therapy (N=1158)
| Landmark, Time, mo |
No. of Patients Excludedb |
No. Who Did Not Progress/ Progressed |
Median OS After Landmark Time, moa |
Adjusted HR (95% CI)a |
Bootstrap Mean (95% CI) for Adjusted HR |
|
|---|---|---|---|---|---|---|
| Did Not Progress |
Progressed | |||||
| 3 | 156 | 834/168 | 23.6 | 7.8 | 3.05 (2.42-3.84) | 3.15 (2.45-4.09) |
| 6 | 299 | 600/259 | 26.0 | 8.6 | 2.96 (2.39-3.67) | 3.06 (2.40-3.87) |
| 9 | 425 | 445/288 | 28.7 | 9.7 | 2.83 (2.26-3.56) | 2.91 (2.17-3.60) |
| 12 | 542 | 330/286 | 32.0 | 11.0 | 3.24 (2.49-4.20) | 3.29 (2.57-4.29) |
OS indicates overall survival; HR, hazard ratio; CI, confidence interval.
a
All OS times were compared in a log-rank analysis and revealed P values <.0001. All adjusted HRs that were calculated using the Heng criteria revealed P values <.0001.
b
Reasons for exclusion: 1) death before landmark time (n=109 [3 mo], n=214 [6 mo], n=285 [9 mo], and n=362 [12 mo]), 2) follow-up for survival or disease not reaching landmark time (n=42 [3 mo], n=80 [6 mo], n=135 [9 mo], n=175 [12 mo]), and 3) missing OS/progression-free survival data (n=5).